|  | 
  
    
    
      | 
          spontaneous nanoliposome antigen particleization         |  
      | Vaxjo ID | 383 |  
      | Vaccine Adjuvant Name | spontaneous nanoliposome antigen particleization |  
      | Adjuvant VO ID | VO_0005665 |  
      | Description | Spontaneous nanoliposome antigen particleization refers to the process of forming nanoliposomes that encapsulate antigens, enhancing their stability and immunogenicity. This method is used to improve vaccine formulations. |  
      | Stage of Development | Research |  
      | Host Species for Testing | Mouse |  
      | Components | SBAS-2 contains MPL and QS21 |  
      | Structure | The structure of the nanoliposomes includes a lipid bilayer that encapsulates the antigen, but specific structural details are not provided in the article. |  
      | Appearance | The appearance of the nanoliposomes is typically described as colloidal dispersions, but specific details are not provided. |  
      | Preparation | The preparation of spontaneous nanoliposome antigen particleization involves the use of lipids and antigens that spontaneously form liposomes under certain conditions, but specific methods are not detailed. |  
      | Function | Antigens are stably presented in uniformly orientated display via his-tag insertion in the cobalt porphyrin-phospholipid bilayer, without covalent modification or disruption of antigen conformation. SNAP immunization of mice and rabbits is well tolerated with minimal local reactogenicity, and results in orders-of-magnitude higher functional antibody generation compared with other 'mix-and-inject' adjuvants. |  
      | Safety | The article does not provide detailed safety information regarding the use of spontaneous nanoliposome antigen particleization in vaccines. |  
	  | References | Lalvani et al., 1999: Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. The Journal of infectious diseases. 1999; 180(5); 1656-1664. [PubMed: 10515829]. |  |